Malaria afflicted 228m, killed 405,000 persons in 2018, WHO report shows
*More pregnant women, children protected from disease but accelerated efforts, funding needed to reinvigorate global response
Thenumber of pregnant women and children in subSaharan Africa sleeping under insecticide-treated bed nets and benefiting from preventive medicine for malaria has increased significantly in recent years, according to the World Health Organisation’s World malaria report 2019. However, accelerated efforts are needed to reduce infections and deaths in the hardest-hit countries, as progress stalls. Last year, malaria afflicted 228 million people and killed an estimated 405,000, mostly in sub-saharan Africa. Pregnancy reduces a woman’s immunity to malaria, making her more susceptible to infection and at greater risk of illness, severe anaemia and death. Maternal malaria also interferes with the growth of the fetus, increasing the risk of premature delivery and low birth weight – a leading cause of child mortality.
“Pregnant women and children are the most vulnerable to malaria, and we cannot make progress without focusing on these two groups,” said Dr. Tedros Adhanom Ghebreyesus, WHO DirectorGeneral. “We’re seeing encouraging signs, but the burden of suffering and death caused by malaria is unacceptable, because it is largely preventable. The lack of improvement in the number of cases and deaths from malaria is deeply troubling.”
In 2018, an estimated 11 million pregnant women were infected with malaria in areas of moderate and high disease transmission in sub-saharan Africa. As a result, nearly 900 000 children were born with a low birthweight.
Despite the encouraging signs seen in the use of preventive tools in pregnant women and children, there was no improvement in the global rate of malaria infections in the period 2014 to 2018.
Inadequate funding remains a major barrier to future progress. In 2018, total funding for malaria control and elimination reached an estimated US$ 2.7 billion, falling far short of the US$ 5 billion funding target of the global strategy.
Last year, WHO and the RBM
Partnership to End Malaria launched “High burden to high impact” (HBHI), a targeted response aimed at reducing cases and deaths in countries hardest hit by malaria. 11 countries that accounted for about 70% of the world’s malaria burden in
2017 are leading the HBHI response. By November 2019, the HBHI approach had been initiated in nine of these countries. Two reported substantial reductions in malaria cases in 2018 over the previous year: India (2.6 million fewer cases) and Uganda (1.5 million fewer cases).
An estimated 61 per cent of pregnant women and children in sub-saharan Africa slept under an insecticidetreated net in 2018 compared to 26 per cent in 2010.
Among pregnant women in the region, coverage of the recommended three or more doses of intermittent preventive treatment in pregnancy (IPTP), delivered at antenatal care facilities (ANC), increased from an estimated 22 per cent in 2017 to 31 per cent in 2018. WHO recommends the use of effective vector control (insecticide-treated nets or indoor residual spraying) and preventive antimalarial medicines to protect pregnant women and children from malaria. Robust health services that provide expanded access to these and other proven malaria control tools – including prompt diagnostic testing and treatment – is key to meeting the goals of the Global technical strategy for malaria 2016-2030 (GTS).
Still, too many women do not receive the recommended number of IPTP doses, or none at all. Some women are unable to access antenatal care services. Others who reach an ANC facility do not benefit from IPTP as the drug is either not available or the health worker does not prescribe it.
For children under five living in Africa’s Sahel subregion, WHO recommends seasonal malaria chemoprevention (SMC) during the high-transmission rainy season. In 2018, 72 per cent of children who were eligible for the preventive medicine benefited from it.
Another recommended strategy – intermittent preventive treatment in infants (IPTI) – calls for delivering antimalarial medicines to very young children through a country’s immunization platform. The tool is currently being pioneered in Sierra Leone.
“IPTI offers a tremendous opportunity to keep small children alive and healthy,” said Dr. Pedro Alonso, Director of WHO’S Global Malaria Programme. “WHO welcomes Unitaid’s new drive, announced today, to accelerate the adoption and scale-up of IPTI in other malaria-endemic countries in sub-saharan Africa.”
Timely diagnostic testing and treatment are vital. But a trained health provider does not bring many children with a fever for care. According to recent country surveys, 36 per cent of children with fever in sub-saharan Africa do not receive any medical attention.
Integrated community case management for malaria, pneumonia and diarrhoea can bridge gaps in clinical care in hard-to-reach communities. Although 30 countries now implement the approach, most sub-saharan African countries struggle to do so, mainly due to bottlenecks in health financing.
Although progress in many high burden countries has stalled, a growing number of countries with a low burden of malaria are moving quickly towards the goal of zero malaria. In 2018, 27 countries reported less than 100 cases of malaria, up from 17 countries in 2010. At least 10 countries that are part of WHO’S “E-2020 initiative” are on track to reach the 2020 elimination milestone of the global strategy. The latest progress report on the “E-2020” initiative is available here.
Globally, WHO has certified a total of 38 countries and territories malaria-free. WHO grants the certification when a country proves, beyond a reasonable doubt, that the chain of indigenous transmission of malaria has been interrupted for at least three consecutive years. The full list of countries can be found here.
The six countries of the Greater Mekong subregion have also made excellent progress. Across the subregion, there was 76 per cent reduction in malaria cases and a 95 per cent drop in deaths between 2010 and 2018. Notably, the report shows a steep decline in cases of P. falciparum malaria, a primary target in view of the ongoing threat of antimalarial drug resistance.